Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

A Sequel to Sanger: amplicon sequencing that scales

Open access
Hebert, Paul D. N., Braukmann, Thomas W. A., Prosser, Sean W. J., Ratnasingham, Sujeevan, deWaard, Jeremy R., Ivanova, Natalia V., Janzen, Daniel H., Hallwachs, Winnie, Naik, Suresh, Sones, Jayme E., Zakharov, Evgeny V.·2018·BMC Genomics

Abstract

BACKGROUND: Although high-throughput sequencers (HTS) have largely displaced their Sanger counterparts, the short read lengths and high error rates of most platforms constrain their utility for amplicon sequencing. The present study tests the capacity of single molecule, real-time (SMRT) sequencing implemented on the SEQUEL platform to overcome these limitations, employing 658 bp amplicons of the mitochondrial cytochrome c oxidase I gene as a model system. RESULTS: By examining templates from more than 5000 species and 20,000 specimens, the performance of SMRT sequencing was tested with amplicons showing wide variation in GC composition and varied sequence attributes. SMRT and Sanger sequences were very similar, but SMRT sequencing provided more complete coverage, especially for amplicons with homopolymer tracts. Because it can characterize amplicon pools from 10,000 DNA extracts in a single run, the SEQUEL can reduce greatly reduce sequencing costs in comparison to first (Sanger) and second generation platforms (Illumina, Ion). CONCLUSIONS: SMRT analysis generates high-fidelity sequences from amplicons with varying GC content and is resilient to homopolymer tracts. Analytical costs are low, substantially less than those for first or second generation sequencers. When implemented on the SEQUEL platform, SMRT analysis enables massive amplicon characterization because each instrument can recover sequences from more than 5 million DNA extracts a year.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12864-018-4611-3

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 280

Metadata

Authors
Hebert, P. D. N., Braukmann, T. W. A., Prosser, S. W. J., Ratnasingham, S., deWaard, J. R., Ivanova, N. V., Janzen, D. H., Hallwachs, W., Naik, S., Sones, J. E., & Zakharov, E. V.
Venue
BMC Genomics
Published
2018-03-27
Volume
19
Issue
1
Pages
219-219
ISSN
1471-2164 (ISSN-L)
OpenAlex
W2949819089
Cited by
280
References
8
FWCI
9.81
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Sequel to Sanger: amplicon sequencing that scales. https://app.cochat.ai/papers/10.1186/s12864-018-4611-3
The paper
Hebert, P. D. N., Braukmann, T. W. A., Prosser, S. W. J., Ratnasingham, S., deWaard, J. R., Ivanova, N. V., Janzen, D. H., Hallwachs, W., Naik, S., Sones, J. E., & Zakharov, E. V. (2018). A Sequel to Sanger: amplicon sequencing that scales. BMC Genomics. https://doi.org/10.1186/s12864-018-4611-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.